Journal Watch · Frontiers in Immunology · 2026

Macrophage metabolic reprogramming in sepsis-associated acute lung injury: mechanisms and therapeutic strategies.

Future strategies should focus on developing cell-type-restricted delivery systems, validating targets in human-relevant models, and designing phase-specific interventions tailored to the metabolic trajectory of S-ALI.

Pan R, Sun Y, Chen L et al.Frontiers in Immunology3 min readPharma relevance 95/100

DOI: 10.3389/fimmu.2026.1808474PMID: 42220522Study type: review / perspective

TL;DR

Future strategies should focus on developing cell-type-restricted delivery systems, validating targets in human-relevant models, and designing phase-specific interventions tailored to the metabolic trajectory of S-ALI.

Key findings

  • Natural compounds, pharmacological inhibitors, and innovative delivery platforms have shown promise in reprogramming macrophage metabolism to restore immune homeostasis.
  • Notable examples include aerosolized CRISPR/Cas9 nanotherapeutics, biomimetic nanoplatforms, pH-responsive nanoparticles, and engineered exosomes.
  • However, challenges such as broad cytotoxicity, limited macrophage selectivity, incomplete pharmacokinetic characterization, and the timing of intervention in the evolving septic milieu must be addressed.
  • Future strategies should focus on developing cell-type-restricted delivery systems, validating targets in human-relevant models, and designing phase-specific interventions tailored to the metabolic trajectory of S-ALI.

What they did

Pro-inflammatory macrophages preferentially utilize aerobic glycolysis and the pentose phosphate pathway, coupled with suppressed oxidative phosphorylation (OXPHOS), whereas reparative macrophages rely predominantly on OXPHOS and fatty acid oxidation (FAO). Key glycolytic enzymes such as PFKFB3 and PKM2, the transcriptional regulator HIF-1α, and TCA cycle intermediates including succinate and itaconate serve as critical metabolic checkpoints governing macrophage inflammatory responses. During S-ALI, the metabolic landscape undergoes dynamic temporal shifts: the early hyperinflammatory phase is characterized by enhanced glycolysis, while the late immunosuppressive phase exhibits impaired OXPHOS and FAO. This review synthesizes recent advances in understanding how metabolic reprogramming orchestrates macrophage polarization during S-ALI, encompassing glycolysis, the TCA cycle, FAO, and amino acid metabolism.

Full abstract (original)

Background: Sepsis-associated acute lung injury (S-ALI) remains a life-threatening condition with high mortality and limited therapeutic options. Macrophages, as key sentinels of innate immunity, exhibit remarkable heterogeneity and functional plasticity. These properties are fundamentally driven by metabolic reprogramming, which tailors their effector functions to specific microenvironmental demands. Beyond the traditional M1/M2 binary classification, macrophage activation is now appreciated as a continuous functional spectrum.

What they did: Pro-inflammatory macrophages preferentially utilize aerobic glycolysis and the pentose phosphate pathway, coupled with suppressed oxidative phosphorylation (OXPHOS), whereas reparative macrophages rely predominantly on OXPHOS and fatty acid oxidation (FAO). Key glycolytic enzymes such as PFKFB3 and PKM2, the transcriptional regulator HIF-1α, and TCA cycle intermediates including succinate and itaconate serve as critical metabolic checkpoints governing macrophage inflammatory responses. During S-ALI, the metabolic landscape undergoes dynamic temporal shifts: the early hyperinflammatory phase is characterized by enhanced glycolysis, while the late immunosuppressive phase exhibits impaired OXPHOS and FAO. This review synthesizes recent advances in understanding how metabolic reprogramming orchestrates macrophage polarization during S-ALI, encompassing glycolysis, the TCA cycle, FAO, and amino acid metabolism.

Results & conclusions: Natural compounds, pharmacological inhibitors, and innovative delivery platforms have shown promise in reprogramming macrophage metabolism to restore immune homeostasis. Notable examples include aerosolized CRISPR/Cas9 nanotherapeutics, biomimetic nanoplatforms, pH-responsive nanoparticles, and engineered exosomes. However, challenges such as broad cytotoxicity, limited macrophage selectivity, incomplete pharmacokinetic characterization, and the timing of intervention in the evolving septic milieu must be addressed. Future strategies should focus on developing cell-type-restricted delivery systems, validating targets in human-relevant models, and designing phase-specific interventions tailored to the metabolic trajectory of S-ALI.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1808474 · PubMed 42220522.

Why it matters for pharma & biotech

  • Directly relevant to teams in gene editing, targeted oncology / immuno-oncology, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: gene editing · targeted oncology / immuno-oncology · small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Frontiers in Immunology study find?

Future strategies should focus on developing cell-type-restricted delivery systems, validating targets in human-relevant models, and designing phase-specific interventions tailored to the metabolic trajectory of S-ALI.

What type of study is this?

It is a review / perspective, published in Frontiers in Immunology in 2026. Pro-inflammatory macrophages preferentially utilize aerobic glycolysis and the pentose phosphate pathway, coupled with suppressed oxidative phosphorylation (OXPHOS), whereas reparative macrophages rely predominantly on OXPHOS and fatty acid oxidation (FAO).

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1808474. PubMed ID: 42220522. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Pan R, Sun Y, Chen L et al.. Macrophage metabolic reprogramming in sepsis-associated acute lung injury: mechanisms and therapeutic strategies.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1808474.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/macrophage-metabolic-reprogramming-in-sepsis-associated-acute-lung-injur-808474/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides